✦ LIBER ✦

The integral role of speech production in the science and treatment of Parkinson's disease

✍ Scribed by Lorraine A. Ramig; Cynthia Fox

Book ID: 112143438
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 58 KB
Volume: 27
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.25046

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Perception and production of emotional s

Perception and production of emotional speech in Parkinson's disease

✍ R. Dengler; C. Schröder; J. Möbes 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 49 KB

The role of subcortical structures in re

The role of subcortical structures in recited speech: Studies in Parkinson's disease

✍ Bridges, Kelly A.; Van Lancker Sidtis, Diana; Sidtis, John J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 295 KB

3.417 The effects of pharmacological tre

3.417 The effects of pharmacological treatment on speech in Parkinson's disease

✍ P. Santens; M. De Letter; G. Van Maele; M. De Bodt; J. Van Borsel 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

The role of opioid receptor agonists and

The role of opioid receptor agonists and antagonists in the treatment of Parkinson’s disease

✍ I. G. Silkis 📂 Article 📅 2007 🏛 SP MAIK Nauka/Interperiodica 🌐 English ⚖ 473 KB

Selegiline ? An overview of its role in

Selegiline ? An overview of its role in the treatment of Parkinson's disease

✍ Wessel, K. ;Szelenyi, I. 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 389 KB

Selegiline (10 mg per day) selectively inhibits monoamine oxidase type B and thus thwarts the metabolism of dopamine by this enzyme. Selegiline has been used in the therapy of Parkinson's disease since 1986. It enhances the efficacy of levodopa, allows a reduction of the levodopa dose, and improves

Role of dopamine receptor agonists in th

Role of dopamine receptor agonists in the treatment of early Parkinson's disease

✍ Ubaldo Bonuccelli; Paolo Del Dotto; Olivier Rascol 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 391 KB